P
Piet M. ter Wee
Researcher at VU University Medical Center
Publications - 30
Citations - 1271
Piet M. ter Wee is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Peritoneal dialysis & Kidney disease. The author has an hindex of 17, co-authored 30 publications receiving 1153 citations.
Papers
More filters
Journal ArticleDOI
Microvascular function relates to insulin sensitivity and blood pressure in normal subjects
Erik H. Serné,Coen D.A. Stehouwer,Coen D.A. Stehouwer,Jan C. ter Maaten,Jan C. ter Maaten,Piet M. ter Wee,Jan A. Rauwerda,Ab J.M. Donker,Reinold O. B. Gans,Reinold O. B. Gans +9 more
TL;DR: Microvascular function strongly relates to insulin sensitivity and blood pressure, consistent with a central role in linking these variables, and part of the variation in both blood pressure and insulin sensitivity could be explained by microv vascular function.
Journal ArticleDOI
Factors Contributing to Peritoneal Tissue Remodeling in Peritoneal Dialysis
Margot N. Schilte,Johanna W.A.M. Celie,Piet M. ter Wee,Robert H.J. Beelen,Jacob van den Born +4 more
TL;DR: Identification of molecular pathways, cells, and cytokines involved in the development of angiogenesis, fibrosis, and membrane failure may lead to innovative therapeutic strategies that can protect the peritoneal membrane from the consequences of long-term PD.
Journal ArticleDOI
SINGLE EXPOSURE OF MESOTHELIAL CELLS TO GLUCOSE DEGRADATION PRODUCTS (GDPs) YIELDS EARLY ADVANCED GLYCATION END- PRODUCTS (AGEs) AND A PROINFLAMMATORY RESPONSE
Angelique G A Welten,Casper G. Schalkwijk,Piet M. ter Wee,Sybren L. Meijer,Jacob van den Born,Robert J H Beelen +5 more
TL;DR: It is demonstrated that MCs take up MGO and 3-DG and form early advanced glycation end-products, evidenced by increased VCAM-1 expression and elevated production of IL-6 and IL-8 and by positive staining with a monoclonal that specifically recognizes MGO-modified proteins, demonstrating complexing to mesothelial cellular proteins.
Journal ArticleDOI
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Lennart Tonneijck,Mark M. Smits,Marcel H. A. Muskiet,Trynke Hoekstra,Trynke Hoekstra,Mark H. H. Kramer,A.H. Jan Danser,Piet M. ter Wee,Michaela Diamant,Jaap A. Joles,Daniël H. van Raalte +10 more
TL;DR: Treatment with sitagliptin or liraglutide does not affect measured renal hemodynamics, tubular functions, and markers of renal damage in overweight patients with type 2 diabetes without chronic kidney disease (CKD).
Journal ArticleDOI
Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (CREAM study)
Birgit C. P. Koch,Karien van der Putten,Eus J.W. Van Someren,Jos P. M. Wielders,Piet M. ter Wee,J. Elsbeth Nagtegaal,Carlo A. J. M. Gaillard +6 more
TL;DR: As melatonin amplitude and melatonin rhythm decreased with advancing renal dysfunction, follow-up research into circadian rhythms in patients with CKD is warranted.